Protease sequences from HIV-1 group M subtypes A - H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide

AIDS

Volumn 14, Issue 11, 2000, Pages 1489-1495

  Pieniazek, Danuta ^a,d   Rayfield, Mark ^a   Hu, Dale J ^a   Nkengasong, John ^b   Wiktor, Stefan Z ^a,b   Downing, Robert ^c   Biryahwaho, Benon ^c   Mastro, Timothy ^a,d   Tanuri, Amilcar ^e   Soriano, Vincent ^f   Lal, Renu ^a   Dondero, Timothy ^d  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Project RETRO CI   (Côte d’Ivoire)

^c UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^d Uganda Virus Research Institute ^*

^e FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Amino acid mutations; HIV 1; Inhibitors; Protease; Resistance; Subtypes

Indexed keywords

PROTEINASE INHIBITOR;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DRUG SENSITIVITY; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; SEQUENCE ANALYSIS; VIRUS MUTATION; VIRUS STRAIN; VIRUS TYPING;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CARBAMATES; CODON; DRUG RESISTANCE, MICROBIAL; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MOLECULAR SEQUENCE DATA; MUTATION; NELFINAVIR; PHYLOGENY; RITONAVIR; SAQUINAVIR; SULFONAMIDES; WORLD HEALTH;

EID: 0033820923     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200007280-00004     Document Type: Article

References (32)

1. HIV-protease inhibitors
2. Active human immunodeficiency virus protease is required for viral infectivity
3. Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles
4. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
5. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
6. Introduction of HIV drug-resistance testing in clinical practice
7. Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients
8. Mutations in retroviral genes associated with drug resistance
9. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays
10. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within Gag/Pol polyproteins: Amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1
11. Pol gene diversity of five human immunodeficiency virus type 1 subtypes: Evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D
12. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors
13. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: Presence of protease inhibitor-resistant variants in untreated subjects
14. Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe
15. Human immunodeficiency virus reverse transcriptase and protease sequence database
16. Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil
17. Limited sequence diversity of the HIV type 1 protease gene from clinical isolates and in vitro susceptibility to HIV protease inhibitors
18. HIV-1 subtypes among blood donors from Rio de Janeiro, Brazil
19. Dual and recombinant infections: An integral part of the HIV-1 epidemic in Brazil
20. Introduction of HIV-2 and multiple HIV-1 subtypes to Lebanon
21. Horizontal and vertical transmission of human immunodeficiency virus type 1 dual infections caused by viruses of subtypes B and C
22. Identification of single and dual infections with distinct subtypes of human immunodeficiency virus type 1 by using restriction fragment length polymorphism analysis
23. Genetic analysis of human immunodeficiency virus in Abidjan, Ivory Coast, reveals predominance of Htype 1 subtype A and introduction of subtype G
24. Fast and sensitive multiple sequence alignments on a microcomputer
25. PHYLIP-phylogeny inference package
26. The genetic data environment and expandable GUI for multiple sequence analysis
27. Optimal alignments in linear space
28. PCR amplification of HIV-1 proteinase sequences directly from lab isolates allows determination of five conserved domains
29. Complete mutagenesis of the HIV-1 protease
30. A molecular epidemiologic survey of HIV in Uganda. HIV Variant Working Group
31. Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates
32. Identification and biased amino acid substitution patterns in human immunodeficiency virus type I isolates from patients treated with protease inhibitors